Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Andernach – page 32

605 clinical trials in Andernach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Andernach at a glance
605
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

605 trials in Andernach

Open in trial search

Primary hyperoxaluria

Not recruiting

Study of nedosiran for patients with primary hyperoxaluria type 1 and severe kidney impairment with or without dialysis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Nedosiran
  • Sponsor:Dicerna Pharmaceuticals Inc.

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lartesertib
  • Sponsor:Merck Healthcare KGaA

Conjunctivitis allergic+1

Not recruiting

Testing sublingual immunotherapy with dermatophagoides pteronyssinus extract for adults with moderate to severe house dust mite allergy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dermatophagoides Pteronyssinus Extract
  • Sponsor:ROXALL Medizin GmbH

Factor VIII deficiency+1

Not recruiting

A study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Denecimig
  • Sponsor:Novo Nordisk A/S

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:4d Molecular Therapeutics Inc.

Short-bowel syndrome

Not recruiting

A Study to Evaluate the Long-Term Safety of Glepaglutide in Adult Patients with Short Bowel Syndrome Who Participated in Previous Studies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag
  • Sponsor:Novartis Pharma AG

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Systemic scleroderma+3

Not recruiting

Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Artiva Biotherapeutics Inc.

Study of zorevunersen to reduce seizures in patients with Dravet syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Zorevunersen sodium
  • Sponsor:Stoke Therapeutics Inc.

Asthmatic crisis

Not recruiting

Long-term safety and effectiveness study of verekitug injections in adults with severe asthma who completed the VALIANT trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Andernach

What the registry says about research in the country

01 Analytical, Diagnostic and Therapeutic Techniques and Equipment

Researchers in Andernach are evaluating innovative cell‑based therapies and delivery platforms aimed at repairing knee cartilage damage.

  • Safety profile of UC‑MSC applied on a collagen scaffold
  • Use of Chondro‑Gide® as a supportive matrix
  • Development of minimally invasive implantation methods
  • Implementation of quantitative outcome tools such as KOOS

Both studies are actively recruiting at the sole research site in Andernach, aiming to generate data that could inform future diagnostic and therapeutic standards.

02 Musculoskeletal Diseases

Clinical efforts focus on restoring damaged knee joint cartilage, a prevalent musculoskeletal concern.

  • Evaluation of minced cartilage implantation (AMCI) versus matrix‑associated autologous chondrocyte implantation
  • Management of full‑thickness knee cartilage lesions
  • Assessment of functional recovery through KOOS scores
  • Exploration of long‑term joint health outcomes

The trials seek to improve treatment options for patients with large cartilage injuries and reflect Andernach’s commitment to advancing musculoskeletal research.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.